EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

PIP Applications assessed by PDCO for the Treatment of Chronic Hepatitis C in Children

- Sophie Olivier, MD, Paediatric Team

Submitted PIPs to the PDCO

- Standard of Care
  - PegInterferon α-2b: Opinion adopted July 2008
  - Ribavirin: Opinion adopted Jul 2008
  - PegInterferon α-2a: Opinion adopted Apr 2010
- DAA in combination with SOC
  - Telaprevir: Opinion adopted Nov 2008
  - TMC 435: Opinion adopted Feb 2010
  - Boceprevir: Opinion adopted Apr 2010
  - BI 201335: Opinion pending
  - Alisporivir in clock-stop

Ribavirin and PegInterferon α-2b

- Single arm efficacy/safety study
- N=100
- Naïve children with evidence inflam/fibrosis
- PEP: SVR24
- 48-w therapy
- 5 years follow-up

PegInterferon α-2a (Pegasys)

- 1 clinical study in children and older
  - RCT pegI/ribavirin vs. pedI alone (PEDS-C trial)
  - Naïve children
  - 48 weeks therapy
  - N= 100
  - PES: SVR24, superiority trial
  - 5 years follow-up
- Extrapolation from adult data
  - for children experienced or HIV co-infected

Telaprevir – PIP 196 – Nov 2008

- 2 clinical studies in children 3 yrs and older
  - BE study chewable vs. adult tablet, single dose
  - Safety/PK/efficacy RCT study, placebo-controlled
    - N = 100 evaluable naïve children genotype 1 with inflam. and/or fibrosis on liver biopsy (within 2 yrs)
    - 8-12 w tritherapy followed by 24-48 w PegI/rib vs. SOC alone
    - PEP: safety
    - SEP: PK, SVR24 (no superiority testing)
    - 5-yr follow-up (sustainability response)
    - Initiation by Dec 2012

TMC 435 – PIP 625 – Feb 2010

- 2 Clinical studies in children 3 yrs and older
  - PK + BE study, single dose
  - RCT efficacy/safety study
    - N= 200 naïve patients genotype 1 at risk for severe or progressive disease, 24 or 48-w tritherapy vs. SOC
    - 50 experienced patients not randomized, 48-w triT
    - PES: SVR24, superiority trial
    - 5-yr follow-up (growth/Tanner, HCV RNA, OPH, TSH/T4)
    - Date of initiation: by June 2013

Boceprevir – PIP 583 – Apr 2010

- 3 clinical studies in children 3 yrs and older
  - PK study, single dose
  - RCT efficacy/safety study
    - N = 200 naïve patients genotype 1 vs. SOC
    - N = 50 experienced patients not randomized
    - 48 weeks treatment
    - PES: SVR24, superiority trial
    - Initiation by Oct 2013
  - Long-term extension study: 5 years
    - Growth, HCV RNA, sexual maturation, OPH exam

PIPs Ongoing Evaluation

- BI 201335
  - RfM in Nov 2009
  - 18 months in clock-stop
  - D61: proposal of single-arm safety study despite claims of consultation with ESPGHAN
- Alisporivir
  - Still in clock stop (15 months)